Oppenheimer Initiates Coverage On Vanda Pharmaceuticals with Outperform Rating, Announces Price Target of $10

Benzinga Newsdesk www.benzinga.com Positive 50.9%

Neg 0% Neu 0% Pos 50.9%

Oppenheimer analyst Les Sulewski initiates coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) with a Outperform rating and announces Price Target of $10.